Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
03/2003
03/06/2003WO2003018606A2 Casein derived peptides and uses thereof in therapy
03/06/2003WO2003018585A1 Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
03/06/2003WO2003018581A1 1,2-dihydro-2-oxo-1,8-naphthyridine derivative
03/06/2003WO2003018580A1 Naphthyridine derivative
03/06/2003WO2003018576A1 New piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity
03/06/2003WO2003018564A1 Vascular wall-selective acat inhibitor
03/06/2003WO2003018556A1 Piperidine derivatives useful as modulators of chemokine receptor activity
03/06/2003WO2003018553A1 Oral antidiabetic agents
03/06/2003WO2003018516A2 Glucagon-like peptide-1 analogs
03/06/2003WO2003018515A2 Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
03/06/2003WO2003018069A1 Preparation and diabetic use of gibberellins
03/06/2003WO2003018059A2 Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
03/06/2003WO2003018044A1 New drug
03/06/2003WO2003018043A1 Compositions and methods for treating subjects with hyperglycemia
03/06/2003WO2003018024A1 Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
03/06/2003WO2003018008A1 Apo ai expression accelerating agent
03/06/2003WO2003018001A1 Apolipo protein e secretion promoters
03/06/2003WO2003017995A1 Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluropropanamide derivatives which elevate pyruvate dehydrogenase activity
03/06/2003WO2003017994A1 Amidine derivatives for treating amyloidosis
03/06/2003WO2003017946A2 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/06/2003WO2003017927A2 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
03/06/2003WO2003017784A1 Herbal nutraceutical formulation for females/expectant mothers and its process of preparation
03/06/2003WO2002102381A9 Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage
03/06/2003WO2002092122A3 Use of osteopontin for the treatment and/or prevention of neurologic diseases
03/06/2003WO2002086069A3 Secreted proteins
03/06/2003WO2002085945A3 Vhh single heavy chain antibody and a method for its preparation in a mammal
03/06/2003WO2002085376A3 A method for decreasing superoxide anion production and for the treatment of diseases associated with oxidative stress
03/06/2003WO2002083066A3 Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
03/06/2003WO2002074249A3 Pharmaceuticals and methods for treating hypoxia and screening methods therefor
03/06/2003WO2002072570A3 Non-imidazole compounds as histamine h3 antagonists
03/06/2003WO2002066516A3 Antibodies that bind both bcma and taci
03/06/2003WO2002064210A3 Combination therapy comprising anti-diabetic and anticonvulsant agents
03/06/2003WO2002060929A3 Polymer conjugates of neublastin and methods of using same
03/06/2003WO2002059302A3 Regulation of human serotonin-like g protein-coupled receptor
03/06/2003WO2002034726A9 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
03/06/2003WO2002024672A3 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
03/06/2003WO2002003984A3 Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x
03/06/2003WO2001092304A3 Transporters and ion channels
03/06/2003WO2001077146A3 Compounds and methods for modulating endothelial cell adhesion
03/06/2003US20030046718 Administering compounds having an effect on cardiac fibrosis, myocardial infarction, defects in electrical conductance, atherosclerosis, unstable plaque, and stroke in an animal which does not express an active SR-BI, and an apolipoprotein
03/06/2003US20030045718 Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
03/06/2003US20030045583 Novel succinate salt of O-desmethyl-venlafaxine
03/06/2003US20030045567 (-)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
03/06/2003US20030045565 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
03/06/2003US20030045560 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
03/06/2003US20030045558 Such as 2-(4-(2-(2-(4-(3,5-dimethyl-isoxazol-4-yl)-phenyl)-5-methyloxazol-4-yl) -ethyoxy)-phenoxy)-2-methylpropionic acid for treatment of diabetes (lowering serum triglycerides)
03/06/2003US20030045556 Aryl-N-cyanoguanidines and methods related thereto
03/06/2003US20030045554 Such as 1-(2-thien-2'-yl- 2-oxoethyl)-3-((3-phenylmethyl) pyrazol-5-yl)pyridinium bromide for treating diseases caused by the accumulation of AGE (Advanced Glycation Endproducts); antidiabetic/ antiaging agents
03/06/2003US20030045553 Peroxisome proliferator-activated receptor agonists (PPAR) for increasing insulin sensitivity in treatment of diabetes and Syndrome X
03/06/2003US20030045544 Bactericides for the oral region of animals using 3-carboxy-4-oxo quinoline or 1,8-naphthyridine derivatives or 1-cyclopropyl-3-carboyx-4-oxo quinolizine derivatives
03/06/2003US20030045540 Nicotinic acetylcholine receptors antagonists; central nervous system disorder treatments
03/06/2003US20030045527 Treating central nervous system or gastrointestinal disorders
03/06/2003US20030045521 Sulfohydroxamic acids and sulfohydroxamates and their use as MEK inhibitors
03/06/2003US20030045519 Treating allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion)
03/06/2003US20030045516 Chemokine receptor antagonists and methods of use therefor
03/06/2003US20030045515 Cyanoguanidine I kappa B kinase inhibitors as antiproliferative agents for cancer treatment
03/06/2003US20030045509 Hydroxyvitamin D characterized by a purity equal to or greater than 98% by a weight-based HPLC assay, residual solvents of 0.5% or less, a total impurity of 1. 5% or less, and no single impurity of greater than 0.5%.
03/06/2003US20030045504 Regulation of fat or lipid metabolism by means of compositions and diets which are high in resistant starch and unsaturated fats; especially for treating non-insulin dependent diabetes mellitus.
03/06/2003US20030045502 Oral intake solution
03/06/2003US20030045501 Use of atazanavir in HIV therapy
03/06/2003US20030045490 Therapeutic antisense phosphodiesterase inhibitors
03/06/2003US20030045478 Treating diseases such as cardiac and cerebral ischemia or reperfusion injury, sepsis and bacterial meningitis.
03/06/2003US20030045475 Reducing the rate of islet cell infiltration by lymphocytes in a diabetes-susceptible mammal by administering a gonadotropin-releasing hormone antagonist.
03/06/2003US20030045470 Methods and compositions for modulating gluconeogenesis using PGC-1
03/06/2003US20030045467 Administering in combination with an oil-based carrier for the prevention and treatment of diabetes type 1
03/06/2003US20030044960 Picornaviruses, vaccines and diagnostic kits
03/06/2003US20030044898 Nucleotide sequences coding polypeptide for use in the treatment of asthma, parkinson's, heart defects, hypotension, urogenital and bone disorders
03/06/2003US20030044893 Nectin polypeptides, polynucleotides, methods of making and use thereof
03/06/2003US20030044514 Using supercritical fluids to infuse therapeutic on a medical device
03/06/2003US20030044474 High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
03/06/2003US20030044391 Preparation and xenotransplantation of porcine islets
03/06/2003US20030041602 Process for production of nanoparticles and microparticles by spray freezing into liquid
03/06/2003CA2458924A1 Casein derived peptides and uses thereof in therapy
03/06/2003CA2458866A1 Compositions and methods of treating diabetes
03/06/2003CA2458849A1 Obesity related genes expressed at least in the hypothalamus, liver or pancreas
03/06/2003CA2458782A1 Compositions and methods for treating subjects with hyperglycemia
03/06/2003CA2458621A1 Oral antidiabetic agents
03/06/2003CA2458565A1 New angiogenesis inhibitors based on soluble cd44 receptor hyaluronic acid binding domain
03/06/2003CA2458375A1 Substituted-heteroaryl-7-aza¬2.2.1|bicycloheptanes for the treatment of disease
03/06/2003CA2458371A1 Glucagon-like peptide-1 analogs
03/06/2003CA2458217A1 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
03/06/2003CA2458121A1 Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluropropanamide derivatives which elevate pyruvate dehydrogenase activity
03/06/2003CA2457976A1 Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
03/06/2003CA2457974A1 Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
03/06/2003CA2457532A1 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/06/2003CA2456349A1 1,2-dihydro-2-oxo-1,8-naphthyridine derivative
03/06/2003CA2455497A1 Amidine derivatives for treating amyloidosis
03/06/2003CA2449515A1 Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
03/05/2003WO2002020566A2 NOVEL MMP-2 DERIVATIVES FOR USE AS INHIBITORS OF INTEGRIN αVβ¿3?
03/05/2003EP1288224A1 Therapeutic peptide derivatives
03/05/2003EP1288223A1 Therapeutic peptide derivatives
03/05/2003EP1288216A1 Tricyclic quinazolinediones
03/05/2003EP1288214A1 Paroxetine methanesulfonate
03/05/2003EP1288206A1 Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors
03/05/2003EP1288205A1 Novel phenylalanine derivatives
03/05/2003EP1288202A1 N-acyltetrahydroisoquinoline derivatives
03/05/2003EP1287825A1 Blends comprising a substituted fatty acid or a derivative thereof
03/05/2003EP1287821A1 Multiparticulate formulations of atorvastatin calcium having a modulated rate of drug release
03/05/2003EP1287354A2 Assay techniques based on growth stage dependent expression in c. elegans
03/05/2003EP1287353A2 Compound screens relating to insulin deficiency or insulin resistance
1 ... 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 ... 1298